About United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio10.77
Forward P/E Ratio9.00
Sales & Book Value
Annual Sales$1.73 billion
Price / Sales2.96
Cash Flow$12.0338 per share
Price / Cash9.75
Book Value$48.64 per share
Price / Book2.41
EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Return on Equity26.68%
Return on Assets19.25%
United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions
What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
How will United Therapeutics' stock buyback program work?
United Therapeutics announced that its Board of Directors has initiated a share buyback plan on Sunday, June 4th 2017, which allows the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 4.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.
How were United Therapeutics' earnings last quarter?
United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported $5.57 EPS for the quarter, beating the Zacks' consensus estimate of $3.62 by $1.95. The biotechnology company had revenue of $389.20 million for the quarter, compared to the consensus estimate of $393.96 million. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.61 earnings per share. View United Therapeutics' Earnings History.
When is United Therapeutics' next earnings date?
What price target have analysts set for UTHR?
8 equities research analysts have issued 12-month price objectives for United Therapeutics' shares. Their forecasts range from $95.00 to $232.00. On average, they expect United Therapeutics' share price to reach $130.75 in the next year. View Analyst Ratings for United Therapeutics.
Who are some of United Therapeutics' key competitors?
Some companies that are related to United Therapeutics include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS) and SAGE Therapeutics (SAGE).
Who are United Therapeutics' key executives?
United Therapeutics' management team includes the folowing people:
- Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
- Mr. Michael I. Benkowitz, Pres & COO (Age 46)
- Mr. James C. Edgemond, CFO & Treasurer (Age 50)
- Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Kevin Gray, Sr. VP of Strategic Operations & Logistics
Has United Therapeutics been receiving favorable news coverage?
Media headlines about UTHR stock have trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are United Therapeutics' major shareholders?
United Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.28%), Palo Alto Investors LP (3.73%), Old Mutual Global Investors UK Ltd. (2.21%), Dimensional Fund Advisors LP (2.20%), FIL Ltd (1.48%) and Thompson Siegel & Walmsley LLC (1.25%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.
Which institutional investors are selling United Therapeutics stock?
UTHR stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Wells Fargo & Company MN, Royal Bank of Canada, Millennium Management LLC, BNP Paribas Arbitrage SA, Thompson Siegel & Walmsley LLC, Swiss National Bank and State of Tennessee Treasury Department. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt, Raymond Dwek and Richard Giltner. View Insider Buying and Selling for United Therapeutics.
Which institutional investors are buying United Therapeutics stock?
UTHR stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, BlackRock Inc., Mackay Shields LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., UBS Group AG, Senzar Asset Management LLC and Ontario Teachers Pension Plan Board. View Insider Buying and Selling for United Therapeutics.
How do I buy shares of United Therapeutics?
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is United Therapeutics' stock price today?
One share of UTHR stock can currently be purchased for approximately $117.33.
How big of a company is United Therapeutics?
United Therapeutics has a market capitalization of $5.11 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.
How can I contact United Therapeutics?
United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]
MarketBeat Community Rating for United Therapeutics (UTHR)MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.